Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism-Reference-Cited by-同舟云学术

Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism

Published:2017-06-20 Issue:9 Volume:158 Page:2722-2740
ISSN:0013-7227
Container-title:Endocrinology
language:en
Short-container-title:

Author:

Shao Yu¹,Hernandez-Buquer Selene²,Childress Paul³,Stayrook Keith R⁴,Alvarez Marta B³,Davis Hannah²,Plotkin Lilian I²,He Yongzheng⁵⁶,Condon Keith W²,Burr David B²,Warden Stuart J⁷⁸,Robling Alexander G²,Yang Feng-Chun⁹,Wek Ronald C¹⁰,Allen Matthew R²¹¹,Bidwell Joseph P¹²

Affiliation:

1. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202

2. Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202

3. Department of Orthopedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202

4. Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana 46202

5. Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana 46202

6. Herman B. Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana 46202

7. Center for Translational Musculoskeletal Research, School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202

8. Department of Physical Therapy, School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, Indiana 46202

9. Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, Florida 33136

10. Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202

11. Richard A. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana 46202

Publisher

The Endocrine Society

Subject

Endocrinology

Link

http://academic.oup.com/endo/article-pdf/158/9/2722/19677647/en.2017-00355.pdf

Reference74 articles.

1. Inhibiting the inhibitor: a new route to bone anabolism;Jilka;J Bone Miner Res,2009

2. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal;Cosman;J Bone Miner Res,2001

3. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers;Kurland;J Clin Endocrinol Metab,2000

4. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety;Vahle;Toxicol Pathol,2002

5. Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet;Cusano;Curr Med Res Opin,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Loss of Nmp4 enhances bone gain from sclerostin antibody administration;Bone;2023-12

2. NMP4, an Arbiter of Bone Cell Secretory Capacity and Regulator of Skeletal Response to PTH Therapy;Calcified Tissue International;2023-05-06

3. Conditional Loss of Nmp4 in Mesenchymal Stem Progenitor Cells Enhances PTH‐Induced Bone Formation;Journal of Bone and Mineral Research;2022-11-22

4. PTHR1 in Bone;GPCRs as Therapeutic Targets;2022-09-16

5. Dose-dependent effects of pharmaceutical treatments on bone matrix properties in ovariectomized rats;Bone Reports;2021-12